LDS/Medical Tests/9p21 Genotype (CVD Risk Genotype Test)

9p21 Genotype (CVD Risk Genotype Test)

Cardiovascular disease is a major of all causes of death in developed countries. Various risk factors like hypercholesterolemia, smoking, hypertension, diabetes, obesity, and lifestyle are all associated with the increased cardiovascular disease (CVD) risk. The Genome-Wide Association Study (GWAS) found that 42 single-nucleotide polymorphisms (SNPs) that were significantly associated with cardiovascular risk. Among these SNPs at location 9p21 showed the strongest associated with CVD risk. One of such genes is located on the short arm (p) of chromosome 9 at position 21. Such SNPs are found to be associated with coronary artery disease (CAD) and patients that carry such abnormalities are susceptible to developing coronary atherosclerosis before the age of 50 in men and before the age of 60 in women.

Two common SNPs of this gene: rs10757278 and rs1333049 are found to be present in nearly 40% of the population and are independent risk factors that are not linked to other known factors. There is a 25% increased risk of developing CAD in patients with abnormalities in one copy of the gene and a 50% increased risk in those with abnormalities in both copies. These variants are associated with a two-fold greater risk of CAD than smoking and hypercholesterolemia. To a lesser extent, the variants are also associated with aortic aneurysms and ischemic stroke.

The approximate mechanism of the underlying risk is largely unclear, but it is attributed to the disruption of the transcription factor binding site of the enhancer sequence of the gene. There are unique risk genotypes for each of the two variants which are described in the interpretation section below. Testing for these variants is beneficial in screening of susceptible individuals, especially those with a familial history of cardiovascular diseases.

  • Risk evaluation for atherosclerosis and coronary heart disease
  • Screening family members with a history of coronary heart disease

Postive:

A positive result indicates the presence of variants in the 9p21 gene indicating increased risk in cardiovascular diseases and atherosclerosis.

A negative result indicates the absence of variants in the 9p21 gene and decrease risk in cardiovascular diseases and atherosclerosis.

Risk to genotype:

rs10757278 A/A (Normal Genotype), A/G (Borderline Genotype), G/G (High Risk Genotype)

rs1333049 G/G (Normal Genotype), C/G (Borderline Genotype), C/C (High Risk Genotype)

Normal variants (rs10757278 A/A, rs1333049 G/G)

Real-time Polymerase chain reaction (PCR) for the targeted sequence/ deletion analysis, next-generation sequencing (NGS), sequencing of the entire coding region.

Whole Blood, Lavender-top (EDTA) tube, buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days (preferred)
Lipid profile, CK-MB, NT-proBNP, cardiac troponins, hs-CRP, Haptoglobin genotype test, KIF6 statin benefit genotype test, 9p21 CVD risk genotype test, PITX2 gene mutation analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login